NURS 5433 Endocrine Thyroid Exam Prep Document |
2026/2027 Edition | 250 Verified Questions
NURS 5433 Module 5 Endocrine Thyroid Exam 2026-2027 QUESTIONS AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation guide covers the endocrine thyroid module for NURS 5433 at
the University of Texas at Arlington. It includes 250 verified questions with detailed rationales,
designed to ensure mastery of thyroid pathophysiology, assessment, diagnostics, and nursing
management. Updated for the 2026/2027 academic year, this resource aligns with current clinical
guidelines and exam blueprints. Achieve a guaranteed pass with this complete A+ guide.
Key Features:
Thyroid hormone synthesis and regulation
Hyperthyroidism and hypothyroidism pathophysiology
Thyroid diagnostic tests and interpretation
Pharmacological and surgical management
Nursing assessment and patient education
Updates for 2026:
- Incorporated 2026 American Thyroid Association guidelines
- Added new questions on thyroid storm management
- Revised rationales to reflect updated evidence-based practice
- Enhanced distractor explanations for common misconceptions
- Updated medication information including newer thyroid agents
Abstract:
This document provides a rigorous review of endocrine thyroid content for NURS 5433 Module 5, featuring 250
exam-style questions with comprehensive rationales. The material covers thyroid anatomy, physiology, and
pathophysiology, emphasizing hyperthyroidism, hypothyroidism, thyroiditis, and thyroid nodules. Diagnostic
evaluation including TSH, free T4, T3, thyroid antibodies, and imaging studies is thoroughly addressed.
Pharmacological interventions such as antithyroid drugs, beta-blockers, and thyroid hormone replacement are
discussed, along with surgical considerations and radioactive iodine therapy. Nursing management focuses on
symptom assessment, monitoring for complications like thyroid storm and myxedema coma, and patient education.
Each question includes correct answer identification, rationale for correct and incorrect options, and clinical
pearls to enhance retention. Updated for 2026/2027, this guide ensures alignment with current clinical practice
and exam expectations.
Keywords:
NURS 5433, Endocrine Thyroid, Thyroid Exam, Hyperthyroidism, Hypothyroidism, Thyroid Storm, Thyroid
Diagnostics, Nursing Management
Answer Format:
Each question is followed by the correct answer and a detailed rationale explaining why it is correct. Incorrect
options are analyzed with distractor explanations to clarify common errors. Clinical pearls and mnemonics are
included to aid memory and application.
Compliance Checklist:
All questions verified against 2026/2027 course objectives
Rationales updated to reflect latest evidence-based guidelines
Content aligns with ANA scope and standards of practice
Page 1
, Medication information reviewed for current FDA approvals
Questions formatted to mimic actual exam style and difficulty
Content Area Overview:
Content Area Questions Key Topics Weight
Thyroid Physiology and 1-40 Hypothalamic-pituitary-thyroid axis, thyroid 16%
Hormone Regulation hormone synthesis, feedback regulation,
peripheral conversion
Hyperthyroidism 41-90 Graves disease, toxic nodular goiter, 20%
thyroiditis, signs/symptoms, thyroid storm
Hypothyroidism 91-140 Primary vs secondary, Hashimoto 20%
thyroiditis, myxedema coma, levothyroxine
therapy
Thyroid Diagnostics and 141-180 TSH, free T4, T3, thyroid antibodies, 16%
Laboratory Interpretation radioactive iodine uptake, ultrasound, biopsy
Pharmacological and Surgical 181-220 Antithyroid drugs, beta-blockers, radioactive 16%
Management iodine, thyroidectomy, complications
Nursing Assessment, Education, 221-250 Nursing care plans, patient education, 12%
and Special Populations pregnancy, pediatric, elderly considerations
Page 2
,Q1. A patient with Graves disease is started on methimazole. After 4 weeks, the TSH is markedly elevated
while free T4 and T3 are low. Which of the following best explains this pattern?
A. Development of primary hypothyroidism due to excessive methimazole dose
B. Pituitary adaptation to rapid decline in thyroid hormone levels
C. Laboratory interference from methimazole metabolites
D. Concomitant autoimmune hypothyroidism (Hashimoto thyroiditis)
Correct Answer: B. Pituitary adaptation to rapid decline in thyroid hormone levels
Rationale: In Graves disease, TSH is suppressed by high T4/T3. With methimazole therapy, thyroid hormone levels
fall, removing negative feedback on the pituitary. The TSH rises to a new steady state, often overshooting before
stabilizing. This is a physiologic pituitary response, not drug-induced hypothyroidism or autoimmune overlap.
Option A is plausible but typically takes longer; option C is not a known interference; option D is possible but less
likely as the primary explanation.
Why Wrong:
A - While excessive methimazole can cause hypothyroidism, the pattern of rising TSH with low free T4/T3
after only 4 weeks is more consistent with pituitary recovery than iatrogenic hypothyroidism, which usually
develops over months.
C - Methimazole does not interfere with standard immunoassays for TSH, free T4, or free T3.
D - Concomitant Hashimoto disease would present with positive TPO antibodies and often a goiter; this is not
the most likely explanation in a patient with known Graves disease on antithyroid drug therapy.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 52; ATA Guidelines for
Hyperthyroidism (2025).
Q2. A patient with a history of atrial fibrillation and well-controlled Graves disease on methimazole presents
with acute-onset palpitations, diaphoresis, and fever. TSH is <0.01 mIU/L, free T4 4.5 ng/dL (normal 0.8-1.8),
free T3 12 pg/mL (normal 2.3-4.2). Which of the following is the most appropriate immediate pharmacologic
intervention?
A. Increase methimazole dose and add propranolol
B. Administer intravenous esmolol and high-dose propylthiouracil (PTU)
C. Start prednisone and potassium iodide
D. Administer intravenous normal saline and sodium bicarbonate
Correct Answer: B. Administer intravenous esmolol and high-dose propylthiouracil (PTU)
Rationale: This presentation is consistent with thyroid storm. The first-line therapy includes high-dose thionamide
(PTU preferred in storm due to its additional inhibition of T4-to-T3 conversion) and beta-blockade (esmolol for
rapid titratability). Option A is insufficient because oral methimazole has slower onset; PTU is preferred in acute
storm. Option C (prednisone and iodide) is adjunctive but not primary. Option D is for other emergencies like DKA
or lactic acidosis.
Why Wrong:
A - Increasing oral methimazole is too slow for thyroid storm; intravenous PTU is preferred for its additional
T4-to-T3 conversion blockade.
C - Prednisone and potassium iodide are adjunctive therapies used to reduce T4 release and peripheral
conversion, but they are not the immediate first-line agents.
D - Normal saline and sodium bicarbonate are not specific for thyroid storm; they may be used for supportive
care but do not address the underlying hyperthyroidism.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 52; ATA Thyroid Storm Guidelines
(2025).
Q3. A patient with hypothyroidism is started on levothyroxine 1.6 mcg/kg/day. After 6 weeks, TSH is 0.1
mIU/L (normal 0.4-4.0) and free T4 is 1.9 ng/dL (normal 0.8-1.8). The patient reports palpitations and
anxiety. What is the most appropriate next step?
Page 3
, A. Reduce levothyroxine dose by 25 mcg and recheck TSH in 6 weeks
B. Switch to liothyronine (T3) to reduce the T4 load
C. Add a beta-blocker and continue current dose
D. Discontinue levothyroxine and start antithyroid medication
Correct Answer: A. Reduce levothyroxine dose by 25 mcg and recheck TSH in 6 weeks
Rationale: The patient has iatrogenic hyperthyroidism (suppressed TSH, elevated free T4, symptoms). The correct management
is to reduce the levothyroxine dose. A typical reduction of 12.5-25 mcg is appropriate. Option B is not indicated; liothyronine
has a shorter half-life and is not preferred for routine management. Option C (adding beta-blocker) treats symptoms but does
not address the cause. Option D is inappropriate because the problem is overtreatment, not new-onset hyperthyroidism.
Why Wrong:
B - Liothyronine is not recommended for routine hypothyroidism due to fluctuating T3 levels and lack of long-term
safety data; it does not correct the iatrogenic hyperthyroidism.
C - Adding a beta-blocker provides symptomatic relief but does not correct the underlying overtreatment; dose reduction
is required.
D - Discontinuing levothyroxine and starting antithyroid medication is incorrect because the patient does not have
intrinsic hyperthyroidism; the issue is excessive exogenous thyroid hormone.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 51; ATA Guidelines for Hypothyroidism (2025).
Q4. Which of the following best explains why radioactive iodine (RAI) therapy is not recommended as
first-line treatment for hyperthyroidism in patients with moderate-to-severe Graves ophthalmopathy?
A. RAI does not reduce TPO antibody titers, leaving the orbital inflammation unchecked
B. RAI can exacerbate ophthalmopathy due to post-therapy TSH receptor antibody surge
C. RAI is ineffective in patients with ophthalmopathy due to orbital fibrosis
D. RAI increases the risk of thyroid cancer in patients with pre-existing eye disease
Correct Answer: B. RAI can exacerbate ophthalmopathy due to post-therapy TSH receptor antibody surge
Rationale: RAI therapy for Graves disease often causes a transient increase in TSH receptor antibodies (TRAbs)
and worsening of ophthalmopathy, especially in smokers or those with pre-existing moderate-to-severe eye disease.
This is thought to be due to antigen release from thyroid destruction. Option A is incorrect because RAI does not
directly affect TPO antibodies. Option C is false; RAI is effective but may worsen eye disease. Option D is not
supported by evidence.
Why Wrong:
A - While RAI may not reduce TPO antibodies, the primary concern is the rise in TRAbs, which directly
stimulate orbital fibroblasts.
C - RAI is effective in treating hyperthyroidism even in patients with ophthalmopathy; the concern is
exacerbation, not lack of efficacy.
D - RAI is not associated with increased thyroid cancer risk in this population; the link is to ophthalmopathy
progression, not malignancy.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 52; ATA Guidelines for Graves
Ophthalmopathy (2025).
Q5. A patient with hypothyroidism is status post Roux-en-Y gastric bypass. The patient reports persistent
fatigue and weight gain despite taking levothyroxine 150 mcg daily. TSH is 8.5 mIU/L. Which of the
following is the most likely cause?
A. Delayed gastric emptying reducing levothyroxine absorption
B. Decreased dissolution of levothyroxine tablets due to altered pH
C. Malabsorption of levothyroxine due to bypassed duodenum and proximal jejunum
D. Increased clearance of levothyroxine due to postoperative hypermetabolism
Correct Answer: C. Malabsorption of levothyroxine due to bypassed duodenum and proximal jejunum
Rationale: Roux-en-Y gastric bypass bypasses the duodenum and proximal jejunum, where levothyroxine is
Page 4
2026/2027 Edition | 250 Verified Questions
NURS 5433 Module 5 Endocrine Thyroid Exam 2026-2027 QUESTIONS AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation guide covers the endocrine thyroid module for NURS 5433 at
the University of Texas at Arlington. It includes 250 verified questions with detailed rationales,
designed to ensure mastery of thyroid pathophysiology, assessment, diagnostics, and nursing
management. Updated for the 2026/2027 academic year, this resource aligns with current clinical
guidelines and exam blueprints. Achieve a guaranteed pass with this complete A+ guide.
Key Features:
Thyroid hormone synthesis and regulation
Hyperthyroidism and hypothyroidism pathophysiology
Thyroid diagnostic tests and interpretation
Pharmacological and surgical management
Nursing assessment and patient education
Updates for 2026:
- Incorporated 2026 American Thyroid Association guidelines
- Added new questions on thyroid storm management
- Revised rationales to reflect updated evidence-based practice
- Enhanced distractor explanations for common misconceptions
- Updated medication information including newer thyroid agents
Abstract:
This document provides a rigorous review of endocrine thyroid content for NURS 5433 Module 5, featuring 250
exam-style questions with comprehensive rationales. The material covers thyroid anatomy, physiology, and
pathophysiology, emphasizing hyperthyroidism, hypothyroidism, thyroiditis, and thyroid nodules. Diagnostic
evaluation including TSH, free T4, T3, thyroid antibodies, and imaging studies is thoroughly addressed.
Pharmacological interventions such as antithyroid drugs, beta-blockers, and thyroid hormone replacement are
discussed, along with surgical considerations and radioactive iodine therapy. Nursing management focuses on
symptom assessment, monitoring for complications like thyroid storm and myxedema coma, and patient education.
Each question includes correct answer identification, rationale for correct and incorrect options, and clinical
pearls to enhance retention. Updated for 2026/2027, this guide ensures alignment with current clinical practice
and exam expectations.
Keywords:
NURS 5433, Endocrine Thyroid, Thyroid Exam, Hyperthyroidism, Hypothyroidism, Thyroid Storm, Thyroid
Diagnostics, Nursing Management
Answer Format:
Each question is followed by the correct answer and a detailed rationale explaining why it is correct. Incorrect
options are analyzed with distractor explanations to clarify common errors. Clinical pearls and mnemonics are
included to aid memory and application.
Compliance Checklist:
All questions verified against 2026/2027 course objectives
Rationales updated to reflect latest evidence-based guidelines
Content aligns with ANA scope and standards of practice
Page 1
, Medication information reviewed for current FDA approvals
Questions formatted to mimic actual exam style and difficulty
Content Area Overview:
Content Area Questions Key Topics Weight
Thyroid Physiology and 1-40 Hypothalamic-pituitary-thyroid axis, thyroid 16%
Hormone Regulation hormone synthesis, feedback regulation,
peripheral conversion
Hyperthyroidism 41-90 Graves disease, toxic nodular goiter, 20%
thyroiditis, signs/symptoms, thyroid storm
Hypothyroidism 91-140 Primary vs secondary, Hashimoto 20%
thyroiditis, myxedema coma, levothyroxine
therapy
Thyroid Diagnostics and 141-180 TSH, free T4, T3, thyroid antibodies, 16%
Laboratory Interpretation radioactive iodine uptake, ultrasound, biopsy
Pharmacological and Surgical 181-220 Antithyroid drugs, beta-blockers, radioactive 16%
Management iodine, thyroidectomy, complications
Nursing Assessment, Education, 221-250 Nursing care plans, patient education, 12%
and Special Populations pregnancy, pediatric, elderly considerations
Page 2
,Q1. A patient with Graves disease is started on methimazole. After 4 weeks, the TSH is markedly elevated
while free T4 and T3 are low. Which of the following best explains this pattern?
A. Development of primary hypothyroidism due to excessive methimazole dose
B. Pituitary adaptation to rapid decline in thyroid hormone levels
C. Laboratory interference from methimazole metabolites
D. Concomitant autoimmune hypothyroidism (Hashimoto thyroiditis)
Correct Answer: B. Pituitary adaptation to rapid decline in thyroid hormone levels
Rationale: In Graves disease, TSH is suppressed by high T4/T3. With methimazole therapy, thyroid hormone levels
fall, removing negative feedback on the pituitary. The TSH rises to a new steady state, often overshooting before
stabilizing. This is a physiologic pituitary response, not drug-induced hypothyroidism or autoimmune overlap.
Option A is plausible but typically takes longer; option C is not a known interference; option D is possible but less
likely as the primary explanation.
Why Wrong:
A - While excessive methimazole can cause hypothyroidism, the pattern of rising TSH with low free T4/T3
after only 4 weeks is more consistent with pituitary recovery than iatrogenic hypothyroidism, which usually
develops over months.
C - Methimazole does not interfere with standard immunoassays for TSH, free T4, or free T3.
D - Concomitant Hashimoto disease would present with positive TPO antibodies and often a goiter; this is not
the most likely explanation in a patient with known Graves disease on antithyroid drug therapy.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 52; ATA Guidelines for
Hyperthyroidism (2025).
Q2. A patient with a history of atrial fibrillation and well-controlled Graves disease on methimazole presents
with acute-onset palpitations, diaphoresis, and fever. TSH is <0.01 mIU/L, free T4 4.5 ng/dL (normal 0.8-1.8),
free T3 12 pg/mL (normal 2.3-4.2). Which of the following is the most appropriate immediate pharmacologic
intervention?
A. Increase methimazole dose and add propranolol
B. Administer intravenous esmolol and high-dose propylthiouracil (PTU)
C. Start prednisone and potassium iodide
D. Administer intravenous normal saline and sodium bicarbonate
Correct Answer: B. Administer intravenous esmolol and high-dose propylthiouracil (PTU)
Rationale: This presentation is consistent with thyroid storm. The first-line therapy includes high-dose thionamide
(PTU preferred in storm due to its additional inhibition of T4-to-T3 conversion) and beta-blockade (esmolol for
rapid titratability). Option A is insufficient because oral methimazole has slower onset; PTU is preferred in acute
storm. Option C (prednisone and iodide) is adjunctive but not primary. Option D is for other emergencies like DKA
or lactic acidosis.
Why Wrong:
A - Increasing oral methimazole is too slow for thyroid storm; intravenous PTU is preferred for its additional
T4-to-T3 conversion blockade.
C - Prednisone and potassium iodide are adjunctive therapies used to reduce T4 release and peripheral
conversion, but they are not the immediate first-line agents.
D - Normal saline and sodium bicarbonate are not specific for thyroid storm; they may be used for supportive
care but do not address the underlying hyperthyroidism.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 52; ATA Thyroid Storm Guidelines
(2025).
Q3. A patient with hypothyroidism is started on levothyroxine 1.6 mcg/kg/day. After 6 weeks, TSH is 0.1
mIU/L (normal 0.4-4.0) and free T4 is 1.9 ng/dL (normal 0.8-1.8). The patient reports palpitations and
anxiety. What is the most appropriate next step?
Page 3
, A. Reduce levothyroxine dose by 25 mcg and recheck TSH in 6 weeks
B. Switch to liothyronine (T3) to reduce the T4 load
C. Add a beta-blocker and continue current dose
D. Discontinue levothyroxine and start antithyroid medication
Correct Answer: A. Reduce levothyroxine dose by 25 mcg and recheck TSH in 6 weeks
Rationale: The patient has iatrogenic hyperthyroidism (suppressed TSH, elevated free T4, symptoms). The correct management
is to reduce the levothyroxine dose. A typical reduction of 12.5-25 mcg is appropriate. Option B is not indicated; liothyronine
has a shorter half-life and is not preferred for routine management. Option C (adding beta-blocker) treats symptoms but does
not address the cause. Option D is inappropriate because the problem is overtreatment, not new-onset hyperthyroidism.
Why Wrong:
B - Liothyronine is not recommended for routine hypothyroidism due to fluctuating T3 levels and lack of long-term
safety data; it does not correct the iatrogenic hyperthyroidism.
C - Adding a beta-blocker provides symptomatic relief but does not correct the underlying overtreatment; dose reduction
is required.
D - Discontinuing levothyroxine and starting antithyroid medication is incorrect because the patient does not have
intrinsic hyperthyroidism; the issue is excessive exogenous thyroid hormone.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 51; ATA Guidelines for Hypothyroidism (2025).
Q4. Which of the following best explains why radioactive iodine (RAI) therapy is not recommended as
first-line treatment for hyperthyroidism in patients with moderate-to-severe Graves ophthalmopathy?
A. RAI does not reduce TPO antibody titers, leaving the orbital inflammation unchecked
B. RAI can exacerbate ophthalmopathy due to post-therapy TSH receptor antibody surge
C. RAI is ineffective in patients with ophthalmopathy due to orbital fibrosis
D. RAI increases the risk of thyroid cancer in patients with pre-existing eye disease
Correct Answer: B. RAI can exacerbate ophthalmopathy due to post-therapy TSH receptor antibody surge
Rationale: RAI therapy for Graves disease often causes a transient increase in TSH receptor antibodies (TRAbs)
and worsening of ophthalmopathy, especially in smokers or those with pre-existing moderate-to-severe eye disease.
This is thought to be due to antigen release from thyroid destruction. Option A is incorrect because RAI does not
directly affect TPO antibodies. Option C is false; RAI is effective but may worsen eye disease. Option D is not
supported by evidence.
Why Wrong:
A - While RAI may not reduce TPO antibodies, the primary concern is the rise in TRAbs, which directly
stimulate orbital fibroblasts.
C - RAI is effective in treating hyperthyroidism even in patients with ophthalmopathy; the concern is
exacerbation, not lack of efficacy.
D - RAI is not associated with increased thyroid cancer risk in this population; the link is to ophthalmopathy
progression, not malignancy.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 52; ATA Guidelines for Graves
Ophthalmopathy (2025).
Q5. A patient with hypothyroidism is status post Roux-en-Y gastric bypass. The patient reports persistent
fatigue and weight gain despite taking levothyroxine 150 mcg daily. TSH is 8.5 mIU/L. Which of the
following is the most likely cause?
A. Delayed gastric emptying reducing levothyroxine absorption
B. Decreased dissolution of levothyroxine tablets due to altered pH
C. Malabsorption of levothyroxine due to bypassed duodenum and proximal jejunum
D. Increased clearance of levothyroxine due to postoperative hypermetabolism
Correct Answer: C. Malabsorption of levothyroxine due to bypassed duodenum and proximal jejunum
Rationale: Roux-en-Y gastric bypass bypasses the duodenum and proximal jejunum, where levothyroxine is
Page 4
